Trial · NCT03773263
New Application of Sequential in Vitro Muturation System for Infertility Patients With Polycystic Ovary Syndrome
NCT03773263, Phase 3, Unknown, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. New Application of Sequential in Vitro Muturation System for Infertility Patients With Polycystic Ovary Syndrome. Trials, record NCT03773263. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03773263
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- New Application of Sequential in Vitro Muturation System for Infertility Patients With Polycystic Ovary Syndrome
- NCT number
- NCT03773263
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 300 participants, estimated
- Lead sponsor
- Sun Yat-sen University
- Conditions
- Polycystic Ovary Syndrome, Infertility
- Interventions
- sequential IVM system, intracytoplasmic sperm injection (ICSI), Thawed embryo transfer (TET), traditional IVM system
- First posted
- 2018-12-12
- Last updated
- 2018-12-12
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical pregnancy rate | 7 weeks gestation | The fetal heart beat in an intrauterine gestational sac under ultrasound will be defined as clinical pregnancy. |
| Secondary | Oocyte maturation rate | 30 and 46 hours after oocyte retrieval | Oocyte maturation rate (%): number of MII oocytes/ number of oocytes retrieved. |
| Secondary | Fertilization rate | 30 and 46 hours after oocyte retrieval | Fertilization rate (%): number of oocytes fertilized/ number of oocytes retrieved. |
| Secondary | Cleavage rate | 24 hours after ICSI | Cleavage rate (%): number of cleavages/ number of 2PN embryos. |
| Secondary | Day 3 embryo rate | 72 hours after ICSI | Day 3 embryo rate (%): number of Day 3 embryos / number of 2PN embryos. |
| Secondary | Good quality embryo rate at cleavage-stage | 72 hours after ICSI | Good quality embryo rate at cleavage-stage (%): number of good quality embryos at cleavage-stage / number of 2PN embryos. |
| Secondary | Number of cycles with available embryo | 72 hours after ICSI | Available embryos will be defined as three days after oocyte retrieval with containing more than 4 cells and grade 1 to 2 or containing 4 cells with a grade of 1. |
| Secondary | Blastulation rate | 144 hours after ICSI | Blastulation rate (%): number of blastocysts / number of 2PN embryos. |
| Secondary | Biochemical pregnancy rate | 4 weeks gestation | A serum β-hCG level above 5 IU/L, which is performed 12 days after embryos transfer, will be defined as biochemical pregnancy. |
| Secondary | Implantation rate | 7 weeks gestation | The implantation rate will be defined as the number of gestational sacs seen on the ultrasound divided by the total number of embryos transferred. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03773263
GET https://conductscience.org/api/trials/v1/NCT03773263/registered